Wuhan Thalys Med Tech Co Ltd (603716) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.03x

Wuhan Thalys Med Tech Co Ltd (603716) has a Cash Flow Reinvestment Rate of 0.03x as of September 2025, reinvesting CN¥1.57 Million (capex CN¥1.57 Million ) from operating cash flow of CN¥54.57 Million. Check Wuhan Thalys Med Tech Co Ltd (603716) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.03x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥1.57 Million
Capex + Investments

Operating Cash Flow

CN¥54.57 Million
CNY

Capital Expenditures

CN¥1.57 Million
CNY

Wuhan Thalys Med Tech Co Ltd Cash Flow Reinvestment Rate (2012–2024)

Historical reinvestment intensity for Wuhan Thalys Med Tech Co Ltd across 9 annual periods. Explore 603716 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Wuhan Thalys Med Tech Co Ltd (2012–2024)

Year-by-year capital reinvestment analysis for Wuhan Thalys Med Tech Co Ltd. For live market cap and broader valuation context, see market cap of Wuhan Thalys Med Tech Co Ltd.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 0.51x CN¥50.33 Million CN¥99.60 Million CN¥23.21 Million ▲ +41.5%
2023 0.36x CN¥44.94 Million CN¥125.89 Million CN¥40.83 Million ▼ -87.5%
2022 2.85x CN¥80.02 Million CN¥28.12 Million CN¥54.64 Million ▼ -90.3%
2020 29.43x CN¥292.68 Million CN¥9.94 Million CN¥127.70 Million ▲ +1449.0%
2019 1.90x CN¥178.47 Million CN¥93.92 Million CN¥96.49 Million ▲ +116.5%
2015 0.88x CN¥40.47 Million CN¥46.11 Million CN¥40.47 Million ▼ -16.8%
2014 1.06x CN¥31.73 Million CN¥30.07 Million CN¥31.73 Million ▼ 0.0%
2013 1.06x CN¥34.35 Million CN¥32.54 Million CN¥34.35 Million ▼ -93.1%
2012 15.20x CN¥41.04 Million CN¥2.70 Million CN¥41.04 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow